Search International and National Patent Collections
Some content of this application is unavailable at the moment.
If this situation persists, please contact us atFeedback&Contact
1. (WO2017137601) METHODS FOR ASSESSING THE TREATMENT RESPONSE OF TNBC PATIENTS TO NEO-ADJUVANT CHEMOTHERAPY BY ANALYSING CPG METHYLATION
Latest bibliographic data on file with the International Bureau

Pub. No.: WO/2017/137601 International Application No.: PCT/EP2017/053070
Publication Date: 17.08.2017 International Filing Date: 10.02.2017
IPC:
C12Q 1/68 (2006.01)
C CHEMISTRY; METALLURGY
12
BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
Q
MEASURING OR TESTING PROCESSES INVOLVING ENZYMES OR MICRO-ORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
1
Measuring or testing processes involving enzymes or micro-organisms; Compositions therefor; Processes of preparing such compositions
68
involving nucleic acids
Applicants:
THERAWIS DIAGNOSTICS GMBH [DE/DE]; Grillparzerstr. 14 81675 München, DE
Inventors:
SCHMITT, Manfred; DE
WILHELM, Olaf G.; DE
NAPIERALSKI, Rudolf; DE
Agent:
ZWICKER, Jörk; DE
Priority Data:
16155279.911.02.2016EP
Title (EN) METHODS FOR ASSESSING THE TREATMENT RESPONSE OF TNBC PATIENTS TO NEO-ADJUVANT CHEMOTHERAPY BY ANALYSING CPG METHYLATION
(FR) PROCÉDÉS POUR ÉVALUER LA RÉPONSE DE PATIENTES SOUFFRANT DE CANCER DU SEIN TRIPLE NÉGATIF (TNBC) À UNE CHIMIOTHÉRAPIE NÉO-ADJUVANTE PAR ANALYSE DE MÉTHYLATION CPG
Abstract:
(EN) The present invention relates to methods for predicting the efficacy of anthracycline-based neo-adjuvant chemotherapy in triple-negative breast cancer. This is achieved by determining epigenetic changes within the PITX2 gene. Detection of the methylation state of Cp G sites in a genomic sequence of PITX2 allows an estimate of the response or failure of an individual breast cancer patient to neo-adjuvant therapy.
(FR) La présente invention concerne des procédés pour prédire l'efficacité d'une chimiothérapie néo-adjuvante à base d'anthracyclines dans un cancer du sein triple négatif. Les procédés consistent à déterminer des modifications épigénétiques dans le gène PITX2. La détection de l'état de méthylation des sites CpG dans une séquence génomique de PITX2 permet d'estimer la réponse ou la résistance d'une patiente individuelle atteinte de cancer du sein à une thérapie néo-adjuvante.
Designated States: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW
African Regional Intellectual Property Organization (ARIPO) (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW)
Eurasian Patent Organization (AM, AZ, BY, KG, KZ, RU, TJ, TM)
European Patent Office (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR)
African Intellectual Property Organization (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG)
Publication Language: English (EN)
Filing Language: English (EN)
Also published as:
EP3414343